Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

May 31, 2007

Conditions
Esophageal Cancer
Interventions
DRUG

carboplatin

Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.

DRUG

celecoxib

400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.

DRUG

paclitaxel

200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.

PROCEDURE

adjuvant therapy

"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."

PROCEDURE

conventional surgery

"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."

PROCEDURE

neoadjuvant therapy

"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."

Trial Locations (1)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT00066716 - Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus | Biotech Hunter | Biotech Hunter